Sputum processing by mechanical dissociation: A rapid alternative to traditional sputum assessment approaches

Clair Barber1,2 | Laurie Lau1 | Jonathan A. Ward1 | Thomas Daniels3 | Alastair Watson1,2 | Karl J. Staples1,2 | Tom M. A. Wilkinson1,2 | Peter H. Howarth1,3,4

1Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, UK
2NIHR Southampton Biomedical Research Centre, Southampton Centre for Biomedical Research, Southampton, UK
3Cystic Fibrosis Unit, University Hospital Southampton NHS Foundation Trust, Southampton, UK
4Respiratory Medicine, University Hospital Southampton NHS Foundation Trust, Southampton, UK

Correspondence
Clair Barber, Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, UK. Email: c.barber@soton.ac.uk

Abstract

Background: Sputum cytology is currently the gold standard to evaluate cellular inflammation in the airways and phenotyping patients with airways diseases. Sputum eosinophil proportions have been used to guide treatment for moderate to severe asthma. Furthermore, raised sputum neutrophils are associated with poor disease control and impaired lung function in both asthma and COPD and small airways disease in cystic fibrosis. However, induced-sputum analysis is subjective and resource heavy, requiring dedicated specialist processing and assessment; this limits its utility in most clinical settings. Indirect blood eosinophil measures have been adopted in clinical care. However, there are currently no good peripheral blood biomarkers of airway neutrophils. A resource-light sputum processing approach could thus help integrate induced sputum more readily into routine clinical care. New mechanical disruption (MD) methods can rapidly obtain viable single cell suspensions from sputum samples.

Aims: The aim of this study was to compare MD sputum processing to traditional methods for cell viability, granulocyte proportions and sputum cytokine analysis.

Methods: Sputum plugs were split and processed using traditional methods and the MD method, and samples were then compared.

Results: The MD method produced a homogeneous cell suspension in 62 s; 70 min faster than the standard method used. No significant difference was seen between the cell viability ($p = 0.09$), or the concentration of eosinophils ($p = 0.83$), neutrophils ($p = 0.99$) or interleukin-8 ($p = 0.86$) using MD.

Conclusion: This cost-effective method of sputum processing could provide a more pragmatic, sustainable means of directly monitoring the airway milieu. Therefore, we recommend this method be taken forward for further investigation.

Keywords
asthma, chronic obstructive pulmonary disease, eosinophil, inflammometry, neutrophil, severe asthma, sputum
1 | INTRODUCTION

Sputum inflammatory profiles have been used clinically in evaluating the heterogeneity of airways diseases such as asthma, chronic obstructive pulmonary disease (COPD) and idiopathic cough1–4 as well as having potential for cystic fibrosis (CF) disease progression.5 Sputum eosinophil proportional measures are recommended to guide treatment for moderate to severe asthma.6–8 For example, steroid treatment can be tapered down when eosinophils are low6 or increased to reduce exacerbation frequency.2,8,9

Raised sputum neutrophils are associated with lung function decline in both asthma10–12 and COPD.1,13 Binary measures used to describe eosinophilia and neutrophilia based on sputum cell profiles identify where disease control may be modifiable. Sputum differential cell counts are not currently adopted as standard clinical practice for CF, yet CF patients with severe small airways disease have higher neutrophil proportions than those with conserved small airways, hence differential cell counts may also guide understanding of CF disease progression.5

Sputum processing for differential cell counting is currently achieved by agitating sputum plugs with a mucolytic to release the cells.14 This is a relatively rapid technique with incubation being as short as 15 min at room temperature. However, mucolytics act through the breakdown of disulphide bonds.15 Therefore, further analysis of the fluid phase measures in the supernatant is compromised. Bafadhel and colleagues showed that 14 proteins, which were sensitive to mucolytics, were measurable using a phosphate-buffered saline (PBS) incubation step prior to mucus breakdown.16 This increased the analytical capacity of the concurrent method of sputum analysis and is favoured by many researchers, and as such this method is currently accepted as the standard.

The addition of a pre-mucolytic step in the concurrent sputum processing method increases sample processing time by around 45 min. Protracted sputum processing times and differential cell counts are resource heavy, demanding dedicated technicians to process and analyse samples.17 These issues have prevented adoption in clinical practice and analysis is mostly confined to specialist centres with a history of respiratory research.1,6,8 This restricted capacity to analyse sputum has highlighted the need for less intensive, technically straightforward means of phenotyping airway disease.17 The identification of a less labour-intensive method of sputum processing would reduce the overall cost of analysis, expand the capacity to directly monitor a broader panel of cells and mediators and offer the opportunity for more widespread adoption of sputum cell counts and targeted phenotypic-based treatment strategies.

The use of a mechanical dissociator uses mechanical disruption (MD) gentle enough to generate a live singe cell suspension from tissue in a fraction of the time needed for traditional cell dissociation. Dissociated cells using this method are viable for cell culture, flow cytometry and migration assays, but this technology is yet to be applied to sputum samples.18 We aimed to run a pilot study to assess the feasibility of utilising an MD method using the gentleMACS cell dissociator for characterising sputum as an efficient alternative to the current sputum processing method. In order to investigate the utility of the MD method, we compared the composition of partially homogenised sputum samples segmented for side-by-side comparison with the Bafadhel processing method.16 Sputum quality, cellular composition and interleukin (IL)-8 concentration were measured for each processing method. Demonstration of a streamlined methodology for analysing inflammatory profiles in the sputum could lead to greater adoption of sputum characterisation for use in guiding treatment in respiratory diseases.

2 | MATERIALS AND METHODS

2.1 | Sputum collection method

Spontaneous sputum samples were collected from 13 anonymised individuals to undertake a small pilot study including healthy controls (n = 6), CF patients (n = 4) and severe asthma patients (n = 3).

2.2 | Sample processing methods

Sputum plugs were isolated from whole samples using fine-tipped forceps and mixed until the sample appeared visibly homogenous. Homogenised plugs were then split for pairwise analysis of two processing methods; the widely accepted 2-step processing method described by Bafadhel and colleagues, referred to within this manuscript as the standard method, and the MD method.16 Each technique provided a cell fraction and PBS supernatant. These methods are described in detail in Figure 1 and below.

For the standard method, samples were incubated for 30 min in eight volumes of PBS, four volumes of supernatant were then removed for mediator analysis and replaced with four volumes of 0.2% DTT for a further 30-min mucolytic incubation.16 For the MD method, eight volumes of PBS were added to the sample, this was then dissociated using the gentleMACS for 2 × 31 s on programme B. These samples were subsequently stored on ice until samples prepared using the standard method were ready for side-by-side comparison of viability and counts.
In keeping with the current accepted practice, the cell fraction was resuspended and counted to assess cell viability and cell density using the trypan blue exclusion method on a Neubauer haemocytometer (Marienfeld Superior 640010). Cytospins were then generated from the remaining cell suspension and stained with haematoxylin and eosin. Cytospins were coded and counted by two operators who were blinded to the sample purification methods, a total of 400 respiratory cells were counted for each sample in each method by each operator. Pairwise differences in cell viability, cell yield, differential cell counts and IL-8 measured in PBS supernatant were analysed to identify where these measures differed according to the processing methods used. Patients were considered “eosinophilic” where eosinophil proportions were greater than or equal to 2% sputum eosinophils and “neutrophilic” where neutrophil proportions were greater than or equal to 61% sputum neutrophils.

2.3 | Statistical analysis

Descriptive statistics were used to explore the normality of the data using IBM SPSS version 26, half of the measures fit a Gaussian distribution. Data were analysed using non-parametric analyses and presented as median values to accommodate non-parametric data distribution. Results of each measure were listed pairwise, pairs were analysed with Wilcoxon Signed-rank test using GraphPad Prism version 8.0. Non-inferiority was assumed where no significant difference was seen between the standard and MD processing methods with $p \geq 0.05$.

3 | RESULTS

We sought to run a pilot study to compare the streamlined MD sputum processing method with the standard processing technique. The MD method used a single processing tube as compared to the standard method which required four tubes and the addition of a mucolytic reagent. The elimination of incubation, centrifugation, additional calculations and pipetting made the process 70 min faster per sample. There were two fewer tubes and pipette tips used with the MD method.

To assess the utility of the streamlined MD procedure in analysing inflammatory profiles in sputum compared with the standard method, we first assessed the comparative viability of purified cells. The cell viabilities between processing methods were not statistically different although slightly higher in samples purified using the standard method, with a median of 48.5% and 60.7% viability for MD and standard method, respectively ($p = 0.094$) (Figure 2A). There was a positive correlation between the cell viability of paired samples processed using the standard and MD method. However, this was only a small positive association (rho = 0.39) and not statistically significant ($p = 0.128$) (Figure 2C).

We next assessed the cell yield of samples purified by MD as compared with the standard method. Samples purified by MD provided significantly higher cell yields as compared with those purified using the standard method, with a median recovery of $8.37 \times 10^6$ versus $6.04 \times 10^6$ cells, respectively ($p = 0.027$) (Figure 2B). Despite a higher yield from MD compared to the standard there was a very strong, significant positive correlation in cell yield between the two processing methods (rho = 0.97) ($p \leq 0.0001$) (Figure 2D).
We subsequently assessed the comparative level of squamous cell contamination between samples processed using the two purification techniques. The level of squamous cell contamination showed a strong positive correlation between paired samples (rho = 0.93, p < 0.0001, Figure 3B). However, levels of squamous cell contamination were statistically lower...
in MD than the standard method, with a median of 10.5% versus 30.5% of the total cell numbers, respectively ($p = 0.023$) (Figure 3A).

Neutrophil and eosinophil proportions are important clinical markers in sputum and thus we compared MD and standard method to see if cells purified from sputum using these techniques were comparable to give consistent clinical phenotyping. Purification by MD and standard method gave similar proportions of neutrophils, with a median of 72.5% and 67.5% of total cell count, respectively ($p = 0.987$) (Figure 4A). There was a fair positive correlation between neutrophil proportions in these paired samples ($\rho = 0.57$) ($p = 0.04$) (Figure 4C). Furthermore, MD and standard processing methods gave similar proportions of eosinophils with a median of 10.3% and 3.5% of total cell counts, respectively ($p = 0.825$) (Figure 4B). Eosinophil proportions between these processing methods had a moderately strong, significant relationship ($\rho = 0.65$) ($p = 0.02$) (Figure 4D).

The sputum classification of “eosinophilic” remained stable in 93% (12/13 patients) and “neutrophilic” in 76% (10/13) of the samples, using the clinical classifications of eosinophilia and neutrophilia being $\geq2\%$ and $\geq61\%$, respectively. Proportions of the remaining cells in the sputum samples were also compared between each processing method (Table 1) and no significant difference was identified for each cell type measured.

Detection of inflammatory cytokines can also give important information about the inflammatory profile of a patient’s airways and has been shown to be increased in samples purified using PBS as opposed to those using DTT. We, therefore, compared IL-8 concentrations in the PBS supernatant samples separated by the standard method as compared with MD. IL-8 concentrations were not dissimilar between the different processing methods, with medians of 13,144 and 10,185 pg/ml for standard and MD, respectively ($p = 0.860$) (Figure 5A). A strong, significant correlation was shown between the two processing methods ($\rho = 0.86$) ($p = 0.0006$) (Figure 5B).

**FIGURE 4** Effect of processing method on sputum neutrophil (A and C) and eosinophil (B and D) proportions. Graphs A and B analysed using Wilcoxon signed-rank test, blue dots represent measures from the standard method of processing and red triangles represent measures from the mechanical disruption (MD) method. Lines show paired samples. Graphs C and D analysed using Spearman’s rho.
DISCUSSION

Phenotyping sputum is important to guide treatment; however, current methods are time-consuming and thus are not widely used in specialist care. Therefore, we aimed to compare the utility of a streamlined method with a widely used standard process to assess its value for broader adoption in guiding the treatment of respiratory diseases. Our study shows that the MD method adequately liberated cells from mucus in order to perform differential cell counts with reasonably consistent granulocyte phenotypes. Furthermore, it gave similar yields and IL-8 concentrations to the longer non-streamlined standard sputum purification method.

Cell viability has been used as a measure of the value of sputum collection methods and thus may be considered an important measure of sputum quality. However, no studies were found which provided conclusive stepwise differences in cell viability in relation to differential cell counts. Sputum viability counts tend to rely on visual inspection using the trypan blue exclusion method on a Neubauer haemocytometer and are therefore subjective. Many studies involving sputum do not report cell viability, some report acceptable cell viability as greater than 70% others have more inclusive quality control of greater than 50% viability. In the absence of a conclusive measure of processing technique effectiveness we measured both cell viability and cell yield to compare processing methods. In this pilot study, we processed spontaneous sputum which is known to be less viable than induced sputum; therefore, values obtained are comparative and may not be referenceable to the values of induced sputum.

Median cell viability was lower using the MD method but measures were not consistently lower and this was not statistically significant. Variability within the sample may have contributed to part of the differences in viability. However, a larger future study would prove useful in more conclusively understanding potential differences in cell viability between these two methods.

Sputum differential cell counts remain the gold standard analysis for moderate to severe asthma. Yet, there are few centres able to provide sputum cell analysis. Arron

| Proportion of each cell type | Median [IQR] | Spearman's rho | Wilcoxon signed-rank test |
|-----------------------------|-------------|----------------|--------------------------|
|                             | Standard method | MD Method | Correlation coefficient (rho) | Significance (p) | Significance (p) |
| % Macrophages               | 13 | 16.0 [22.5] | 18.5 [23.85] | 0.776 | 0.003 | 0.455 |
| % Columnar epithelial cells | 13 | 0.00 [0.75] | 0.15 [1.65] | 0.505 | 0.085 | 0.281 |
| % Lymphocytes               | 13 | 0.00 [1.0] | 0.65 [0.75] | 0.359 | 0.226 | 0.180 |

Note: Median, [Inter quartile range]. Correlations between the standard and mechanical disruption (MD) methods analysed using Spearman’s rho. Differences between methods used analysed using Wilcoxon signed-rank. Indicated in bold are values which are statistically significant with p < 0.05.

FIGURE 5 Effect of processing method on IL-8 detection. Graph A IL-8 concentrations in PBS sputum supernatant using each processing technique analysed using Wilcoxon signed-rank test, blue dots represent measures from the standard method of processing and red triangles represent measures from the mechanical disruption (MD) method. Lines show paired samples. Graph B IL-8 concentrations in sputum supernatant analysed using Spearman’s rho.
and colleagues identified the need for technically straightforward means of phenotyping asthma because current sputum processing techniques are time and resource heavy.¹⁷

Yet, Brightling and colleagues argue that the healthcare burden of exacerbations, key drivers of respiratory disease progression, exceed the cost of sputum analysis and recommend sputum analysis be available in all specialist centres.¹,⁴,²⁴–²⁶

As our understanding of the diseased lung evolves, a cost-effective, technically straightforward and direct window to the lung would provide a broader, more cost-effective analytical platform than seeking surrogate indirect measures for each emerging treatable trait of each respiratory disease.¹,⁵,¹⁰–¹² Any additional mediator measures available from sputum supernatant would provide the additional potential to understand emerging knowledge of the airway milieu in disease.

Unlike differential cell counts in blood which are often automated, sputum differential cell counts are performed by visual inspection and manual counting of over 400 cells per expectoration. This measure, therefore, remains subjective and requires specialist training. Fluid phase markers measured in PBS sputum supernatant can distinguish between granulocytic phenotypes in both asthma and COPD¹⁶,²⁷ and appear stable.²⁸ Although differential cell counts are a useful measure of granulocyte presence they give no indication of granulocyte activation. Fluid phase markers of granulocyte activity correlate more strongly with asthma control and lung function than granulocyte proportion.²⁹ As expected, IL-8 remained detectable and consistent when measured in PBS supernatant from the standard and MD processing methods. If the other markers reported by Bafadhel¹⁶ are also intact in the MD sample processing method this could eliminate the need for any subjective, specialist analysis of sputum in the absence of useful automated differential cell counts.

The MD method is 70 min faster and a more technically straightforward process for obtaining sputum cells and fluid phase markers in PBS for analysis. Studies requiring a differential cell count and cytokines may be able to use the MD method to increase processing capacity, facilitating clinical lung research. The MD method requires an initial investment of a mechanical cell dissociator. However, the overall reduction in resource demands using the MD processing methods could make sputum analysis available to a wider patient population which is likely to improve patient care. Future development and validation of fully automated techniques will, however, be essential for the full introduction of sputum analysis into everyday care.

The limitations of this pilot study include the small number of spontaneous sputum samples at a single study site. This, therefore, made it difficult to demonstrate reproducibility and conclusively rule out potential differences in viability and cell-type proportions between the two methods which may be distinguishable in a future larger multicentre study. Spontaneous sputum samples were used for this pilot study, yet cell viability is lower in spontaneous sputum,¹⁹ further analysis would benefit from the use of induced sputum. Differential cell counts did, however, have a fair to strong positive correlation between MD and standard processing methods. Samples were not split for dual analysis using the same technique, nor were patients requested to produce repeated samples, samples were not spiked to demonstrate uniformity when sputum samples were split. Therefore, any differences may be attributable to differences in the plugs. Sputum plug consistency may also vary across disease pathologies through differences in cell concentration or properties of the mucus. Larger studies of sputum from a breadth of diseases encompassing these additional considerations will be useful to investigate the power of these analyses in a range of different samples in the future.

In summary, the MD method is a potential alternative technique for sputum processing compared to the current slow and resource-intensive method. In this pilot study, this new method was quicker and more streamlined and showed no inferiority to the current processing methods with regards to cell viability, cell yield, granulocytic phenotype or protein stability.

ACKNOWLEDGMENTS

The authors wish to thank the patients who participated in this study. They also wish to acknowledge the support of the NIHR Southampton Biomedical Research Centre funded by the National Institute for Health Research.

CONFLICT OF INTEREST

TW reports personal fees and others from MyMHealth, grants from GSK, grants and personal fees from AstraZeneca, grants and personal fees from Synairgen, personal fees from BI, outside the submitted work. PH reports employment by GSK outside the submitted work. CB, LL, JW, TD, AW and KS have no conflicts of interest to disclose.

AUTHOR CONTRIBUTIONS

Conceptualisation and supervision: Laurie Lau; Methodology and investigation: Laurie Lau, Clair Barber; Resources: Peter H. Howarth, Thomas Daniels; Formal analysis, Data curation and writing of original draft: Clair Barber; Validation: Jonathan A. Ward; Writing, review and editing and approved final manuscript: all authors.

DATA AVAILABILITY STATEMENT

Any additional data or information related to the study are available upon reasonable request to the corresponding author.
ETHICS
Healthy control and severe asthma samples were collected under ethics number 09/H0502/37, CF samples were collected under ethics number 08/H0502/126, both approved by Southampton and South West Hampshire Research Ethics Committee.

ORCID
Clair Barber https://orcid.org/0000-0001-5335-5129
Alastair Watson https://orcid.org/0000-0002-6735-2567
Karl J. Staples https://orcid.org/0000-0003-3844-6457

REFERENCES
1. Brightling CE. Clinical applications of induced sputum. Chest. 2006;129(5):1344-1348.
2. Kim VL, Coombs NA, Staples KJ, et al. Impact and associations of eosinophilic inflammation in COPD: analysis of the AERIS cohort. Eur Respir J. 2017;50(4):1700853.
3. Powrie DJ, Wilkinson TMA, Donaldson GC, et al. Effect of tiotropium on sputum and serum inflammatory markers and exacerbations in COPD. Eur Respir J. 2007;30(3):472-478.
4. Wilkinson T, Wedzicha JA. Strategies for improving outcomes of COPD exacerbations. Int J Chron Obstruct Pulmon Dis. 2006;1(3):335-342.
5. Eckrich J, Zissler UM, Serve F, et al. Airway inflammation in mild cystic fibrosis. J Cyst Fibros. 2017;16(1):107-115.
6. Boulet L-P. Global Strategy for Asthma Management and Prevention. Global Initiative for Asthma; 2020.
7. British Thoracic Society SIGNBGoatma. BTS/SIGN Asthma Quick Reference Guide 2019. 2019.
8. Petsky HL, Li A, Chang AB. Tailored interventions based on sputum eosinophils versus clinical symptoms for asthma in children and adults. Cochrane Database Syst Rev. 2017;8:CD005603.
9. Mayhew D, Devos N, Lambert C, et al. Longitudinal profiling of the lung microbiome in the AERIS study demonstrates repeatability of bacterial and eosinophilic COPD exacerbations. Thorax. 2018;73(5):422-430.
10. Simpson JL, Scott R, Boyle MJ, Gibson PG. Inflammatory subtypes in asthma: assessment and identification using induced sputum. Respirology. 2006;11(1):54-61.
11. Hastie AT, Moore WC, Meyers DA, et al. Analyses of asthma severity phenotypes and inflammatory proteins in subjects stratified by sputum granulocytes. J Allergy Clin Immunol. 2010;125(5):1028-1036.e1013.
12. Hinks TSC, Brown T, Lau LCK, et al. Multidimensional endotyping in patients with severe asthma reveals inflammatory heterogeneity in matrix metalloproteinases and chitinase 3-like protein 1. J Allergy Clin Immunol. 2016;138(1):61-75.
13. Day K, Ostridge K, Conway J, et al. Interrelationships among small airways dysfunction, neutrophilic inflammation, and exacerbation frequency in COPD. Chest. 2020. https://doi.org/10.1016/j.chest.2020.11.018
14. Popov T, Gottschalk R, Kolenowicz R, Dolovich J, Powers P, Hargreave FE. The evaluation of a cell dispersion method of sputum examination. Clin Exp Allergy. 1994;24(8):778-783.
15. Nicholas B, Djukanovic R. Induced sputum: a window to lung pathology. Biochem Soc Trans. 2009;37(Pt 4):868-872.
16. Bafadhel M, McCormick M, Saha S, et al. Profiling of sputum inflammatory mediators in asthma and chronic obstructive pulmonary disease. Respiration. 2012;83(1):36-44.
17. Aarron JR, Izuvara K. Asthma biomarkers: what constitutes a ‘gold standard’? Thorax. 2015;70(2):105-107.
18. Fujiwara K, Ohuchida K, Sada M, et al. CD166/ALCAM expression is characteristic of tumorigenicity and invasive and migratory activities of pancreatic cancer cells. PLoS One. 2014;9(9):e107247.
19. Bhownik A, Seemungal TA, Sapsford RJ, Devalia JL, Wedzicha JA. Comparison of spontaneous and induced sputum for investigation of airway inflammation in chronic obstructive pulmonary disease. Thorax. 1998;53(11):953-956.
20. Lay JC, Peden DB, Alexis NE. Flow cytometry of sputum: assessing inflammation and immune response elements in the bronchial airways. Inhalation Toxicol. 2011;23(7):392-406.
21. Spannevello A, Beghe B, Bianchi A, et al. Comparison of two methods of processing induced sputum: selected versus entire sputum. Am J Respir Crit Care Med. 1998;157(2):665-668.
22. Ward R, Woltmann G, Wardlaw AJ, Pavord ID. Between-observer repeatability of sputum differential cell counts. Influence of cell viability and squamous cell contamination. Clin Exp Allergy. 1999;29(2):248-252.
23. Newby C, Agbetile J, Hargadon B, et al. Lung function decline and variable airway inflammatory pattern: longitudinal analysis of severe asthma. J Allergy Clin Immunol. 2014;134(2):287-294.
24. Wedzicha JA, Wilkinson T. Impact of chronic obstructive pulmonary disease exacerbations on patients and payers. Proc Am Thorac Soc. 2006;3(3):218-221.
25. Watson A, Spalluto CM, McCrake C, et al. Dynamics of IFN-β responses during respiratory viral infection. Insights for therapeutic strategies. Am J Respir Crit Care Med. 2020;201(1):83-94.
26. Sanei F, Wilkinson T. Influenza vaccination for patients with chronic obstructive pulmonary disease: understanding immunogenicity, efficacy and effectiveness. Ther Adv Respir Dis. 2016;10(4):349-367.
27. Wilkinson TMA, Aris E, Bourne SC, et al. Drivers of year-to-year variation in exacerbation frequency of COPD: analysis of the AERIS cohort. ERJ Open Res. 2019;5(1):00248-02018.
28. Wang F, Liang Z, Yang Y, et al. Reproducibility of fluid-phase measurements in PBS-treated sputum supernatant of healthy and stable COPD subjects. Int J Chron Obstruct Pulmon Dis. 2019;14:835-852.
29. Barber C, Azim A, Ward JA, et al. Concordance in temporally distinct blood and sputum inflammatory phenotypic measures in severe asthma. Eur Respir J. 2019;54(suppl 63):PA5039.

How to cite this article: Barber C, Lau L, Ward JA, et al. Sputum processing by mechanical dissociation: A rapid alternative to traditional sputum assessment approaches. Clin Respir J. 2021;15:800–807. https://doi.org/10.1111/crj.13365